We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
126
Sutro Biopharma
STRO
$411M
$2.07M 0.09%
22,990
-2,010
-8% -$243K
NTLA icon
127
Intellia Therapeutics
NTLA
$1.55B
$2.05M 0.09%
150,290
+81,619
+119% +$1.52M
WAT icon
128
Waters Corp
WAT
$37.3B
$2.04M 0.09%
10,800
– –
ARNA
129
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.04M 0.09%
52,262
-41,505
-44% -$1.63M
XNCR icon
130
Xencor
XNCR
$1.59B
$2.03M 0.09%
+56,172
New +$2.06M
MTD icon
131
Mettler-Toledo International
MTD
$27.9B
$1.98M 0.08%
3,500
– –
HR
132
DELISTED
Healthcare Realty Trust Incorporated
HR
$1.93M 0.08%
68,000
– –
IOVA icon
133
Iovance Biotherapeutics
IOVA
$2.09B
$1.92M 0.08%
216,908
– –
MYOK
134
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.89M 0.08%
38,600
– –
MASI
135
DELISTED
Masimo
MASI
$1.83M 0.08%
17,011
-17,009
-50% -$1.9M
EDIT icon
136
Editas Medicine
EDIT
$413M
$1.74M 0.07%
76,668
– –
PBYI icon
137
Puma Biotechnology
PBYI
$402M
$1.7M 0.07%
83,340
– –
INGN icon
138
Inogen
INGN
$174M
$1.68M 0.07%
+13,500
New +$2.22M
TFX icon
139
Teleflex
TFX
$5.86B
$1.65M 0.07%
6,379
– –
ACIU icon
140
AC Immune
ACIU
$241M
$1.62M 0.07%
171,813
– –
PRGO icon
141
Perrigo
PRGO
$1.43B
$1.45M 0.06%
37,300
– –
NUVA
142
DELISTED
NuVasive, Inc.
NUVA
$1.43M 0.06%
28,816
+9,236
+47% +$556K
AERI
143
DELISTED
Aerie Pharmaceuticals
AERI
$1.4M 0.06%
38,770
– –
RDY icon
144
Dr. Reddy's Laboratories
RDY
$9.85B
$1.38M 0.06%
+182,500
New +$1.28M
CLVS
145
DELISTED
Clovis Oncology, Inc.
CLVS
$1.35M 0.06%
75,400
– –
ICPT
146
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.34M 0.06%
+13,348
New +$1.38M
PTGX icon
147
Protagonist Therapeutics
PTGX
$8.92B
$1.33M 0.06%
197,138
-21,904
-10% -$174K
ADAP
148
DELISTED
Adaptimmune Therapeutics
ADAP
$1.31M 0.06%
228,496
-123,122
-35% -$908K
WHWK
149
Whitehawk Therapeutics
WHWK
$190M
$1.3M 0.06%
51,000
– –
SNR
150
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.3M 0.06%
314,747
-214,172
-40% -$1.13M
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.